Over recent decades, the global burden of fungal disease has expanded dramatically. It is
estimated that fungal disease kills approximately 1.5 million individuals annually; however …

Hybrid molecule approach of drug design has become popular due to advantages such as
delayed resistance, reduced toxicity, ease of treatment of co-infection and lower cost of …

Due to their eukaryotic heritage, the differences between a fungal pathogen's molecular
makeup and its human host are small. Therefore, the discovery and subsequent …

The use of antifungal drugs in the therapy of fungal diseases can lead to the development of
antifungal resistance. Resistance has been described for virtually all antifungal agents in …

The high incidence of fungal infections has become a worrisome public health issue, having
been aggravated by an increase in host predisposition factors. Despite all the drugs …

Improved understanding of basic mycological, pharmacological, and immunological
processes has led to important advances in the diagnosis and treatment of invasive fungal …

This Special Issue of Pharmaceuticals describes recent advances accomplished in the field
of antifungal development, especially the discovery of new drugs and drug repurposing. The …

Invasive fungal infections are a strong contributor to healthcare costs, morbidity and
mortality, especially amongst hospitalized patients. Historically, Candida was responsible for …

Invasive fungal infections cause 1.6 million deaths annually, primarily in
immunocompromised individuals. Mortality rates are as high as 90% due to limited …

Recent investigations have yielded both profound insights into the mechanisms required by
pathogenic fungi for virulence within the human host, as well as novel potential targets for …